Andrew Cleeland takes the helm at the Fogarty Institute

by | Jan 1, 2017 | Fogarty Innovation

Talented leaders display a passion for what they do and inspire action. Already, our staff and entrepreneurs have encountered these attributes in the few short weeks that Andrew Cleeland has been overseeing the Fogarty Institute since he joined as CEO on January 9.

“Andrew is a proven leader who will advance the Institute’s mission to promote medical innovation,” said Dr. Tom Krummel, Fogarty Institute for Innovation chairman of the board of directors. “He was selected following an extensive search of qualified candidates and quickly rose to the top based on his credentials, including his industry relationships, understanding of our core values and culture and the innovative mindset of Silicon Valley. His extensive experience in the medical technology industry and expertise in successful startup companies will be invaluable in helping us bring innovative lifesaving devices to market faster.”

Andrew brings nearly 30 years of experience in the medtech field. He currently also holds the position of vice president and general manager of Medtronic’s Transcatheter Mitral Valve Replacement (TMVR) Venture, formerly Twelve Inc., where he was president and CEO, and serves as vice chairman of The Foundry. He succeeds Ann Fyfe, who led the Institute for five years.

“I have long been impressed with the Fogarty Institute’s excellent work and the legacy it has built of supporting the next generation of innovators and launching successful startups that will transform the future of healthcare,” said Andrew. “I look forward to building on its successful 10-year track record — strengthening and broadening our partnerships, overseeing the addition of new startups and the Institute’s upcoming expansion on the El Camino Hospital campus, and continuing to explore areas where we can effectively make the biggest impact to improve patient care.”

Andrew joined Medtronic following the acquisition of Twelve Inc. Prior to Twelve, he was the president and CEO of Ardian, the pioneer of renal denervation for hypertension, heart failure and other associated disorders. Medtronic acquired Ardian in 2011 in one of the largest venture-funded exits in medtech history.

Andrew also serves on the board of nVision Medical, a Fogarty Institute alum.

  • Search by category: